Future studies will focus on analyzing the correlation between circulating (serum/plasma) and tissue-based ONECUT2 gene-body DNA methylation at clinically relevant time points, with the goal of establishing its utility as a minimally invasive biomarker for risk stratification and disease monitoring in PCa. This evidence concerns the gene ONECUT2 and posterior cortical atrophy.